Five-session prostate radiation better preserves bowel quality of life, trial finds
Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) with moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients with localized intermediate-risk prostate cancer indicate that SBRT improved bowel health-related quality of life (HRQOL) in this patient population. There was no significant improvement with SBRT in…
A recent clinical study, NRG-GU005, has found that stereotactic body radiation therapy (SBRT) is better at preserving bowel quality of life in patients with localized intermediate-risk prostate cancer compared to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT). The trial, published in JAMA, involved 698 patients and compared the two radiation techniques.
While SBRT did not show significant improvements in urinary HRQOL or disease-free survival, it was associated with a positive outcome in the EPIC-26 bowel-domain quality-of-life measure. The study also found that SBRT had lower incontinence-related quality of life and improved maintenance of erectile function compared to IMRT. Lead author Rodney J. Ellis, MD, emphasized the importance of further follow-up to assess the longer-term results.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
